• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Differences in IgG autoantibody Fab glycosylation across autoimmune diseases
CONCLUSION: Our data indicate that in chronic but not acute B cell-mediated autoimmune diseases disease-specific autoantibodies are enriched for Fab glycans.PMID:36716825 | DOI:10.1016/j.jaci.2022.10.035
Source: Herpes - January 30, 2023 Category: Infectious Diseases Authors: Jana Koers Rocco Sciarrillo Ninotska I L Derksen Esther M Vletter Yvonne E Filli é-Grijpma Elisabeth Raveling-Eelsing Nuno A G Gra ça Thiemo Leijser Hendri H Pas L Laura van Nijen-Vos Maaike V J Braham Anne-Marie Buisman Jan de Jong Angela I Schriek Ann Source Type: research

Science ’s 2022 Breakthrough of the Year: A telescope’s golden eye sees the universe anew
html { scroll-behavior: smooth; } .news-article-content--featured>.bodySection>.mb-2x:not(:first-of-type) { display: none; } h3 { scroll-margin-top: 5rem; } .parent-section h3, .subsection h3 { font-size: 1.375rem; line-height: 1.875rem; } .news-article-content-footer h2 { display: none; } .toc img { padding-bottom: 16px; transition: opacity .25s; } .toc img:hover { opacity: 60%; } .toc .image-grid img { padding-bottom: 16px; padding-top: 16px; } .image-grid .news-article__figure__image__wrapper:before, .image-grid .news-article__figure__image__wrapper:after { display: none; } .news-article-content sectio...
Source: ScienceNOW - December 15, 2022 Category: Science Source Type: news

Live Herpes Zoster Vaccine Fails to Provide Long-Term Protection in RA Patients on Tofacitinib Live Herpes Zoster Vaccine Fails to Provide Long-Term Protection in RA Patients on Tofacitinib
The live herpes zoster vaccine does not provide reliable long-term protection in rheumatoid arthritis (RA) patients taking tofacitinib, a recent study suggests.Reuters Health Information
Source: Medscape Allergy Headlines - April 20, 2020 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

Editorial: Shaping of Human Immune System and Metabolic Processes by Viruses and Microorganisms
Conclusions In conclusion, articles in this Research Topic made a very significant contribution to our understanding of the role played by environmental factors, dysbiotic conditions, and infections in triggering diseases. Since this is a rapidly expanding area of research, many other factors contributing to the onset of these diseases are not covered here. We are confident, however, that further studies will expand the list as well as bring a better understanding of mechanisms involved in the onset of autoimmune and autoinflammatory diseases. Author Contributions All authors listed have made a substantial, direct and i...
Source: Frontiers in Microbiology - April 16, 2019 Category: Microbiology Source Type: research

Cellular Immune Function in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
This study was carried out in accordance with the recommendations of The London School of Hygiene & Tropical Medicine (LSHTM) Research Ethics Committee (Ref. 6123) and the National Research Ethics Service (NRES) London-Bloomsbury Research Ethics Committee (REC ref. 11/10/1760, IRAS ID: 77765), with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the LSHTM Research Ethics Committee and the NRES London-Bloomsbury Research Ethics Committee. Author Contributions JC, HD, LN, EL, and ER devised the study ...
Source: Frontiers in Immunology - April 15, 2019 Category: Allergy & Immunology Source Type: research

The Pivotal Role of Regulatory T Cells in the Regulation of Innate Immune Cells
This study was provided by the Canadian Institutes of Health Research and the Manitoba Health Research Council. Conflict of Interest Statement The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. References 1. Sprent J, Kishimoto H. The thymus and central tolerance. Philos Trans R Soc Lond B Biol Sci. (2001) 356:609–16. doi: 10.1098/rstb.2001.0846 PubMed Abstract | CrossRef Full Text | Google Scholar 2. Sakaguchi S, Wing K, Miyara M. Regulatory T cells - a brief history and perspective...
Source: Frontiers in Immunology - April 8, 2019 Category: Allergy & Immunology Source Type: research

Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis
Conclusions The rate of zoster associated with tofacitinib was approximately double that observed in patients using biologics.
Source: Annals of the Rheumatic Diseases - September 8, 2016 Category: Rheumatology Authors: Curtis, J. R., Xie, F., Yun, H., Bernatsky, S., Winthrop, K. L. Tags: Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
Conclusions Tofacitinib demonstrated efficacy in both bDMARD-naive and bDMARD-IR patients with RA. Clinical response to tofacitinib was generally numerically greater in bDMARD-naive than bDMARD-IR patients. The safety profile appeared similar between subpopulations. Trial registration numbers (NCT00413660, NCT0050446, NCT00603512, NCT00687193, NCT00960440, NCT00847613, NCT00814307, NCT00856544, NCT00853385).
Source: Annals of the Rheumatic Diseases - June 9, 2016 Category: Rheumatology Authors: Charles-Schoeman, C., Burmester, G., Nash, P., Zerbini, C. A. F., Soma, K., Kwok, K., Hendrikx, T., Bananis, E., Fleischmann, R. Tags: Open access, Immunology (including allergy), Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis
Conclusions Within the global tofacitinib RA development programme, TB was the most common OI reported but was rare in regions of low and medium TB incidence. Patients who screen positive for latent TB can be treated with isoniazid during tofacitinib therapy.
Source: Annals of the Rheumatic Diseases - May 9, 2016 Category: Rheumatology Authors: Winthrop, K. L., Park, S.-H., Gul, A., Cardiel, M. H., Gomez-Reino, J. J., Tanaka, Y., Kwok, K., Lukic, T., Mortensen, E., Ponce de Leon, D., Riese, R., Valdez, H. Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
Conclusions Treatment with peficitinib as monotherapy for 12 weeks in Japanese patients with moderate to severe RA is efficacious and showed acceptable safety profile. These findings support further developments of peficitinib for RA treatment. Trial registration number NCT01649999; Results.
Source: Annals of the Rheumatic Diseases - May 9, 2016 Category: Rheumatology Authors: Takeuchi, T., Tanaka, Y., Iwasaki, M., Ishikura, H., Saeki, S., Kaneko, Y. Tags: Open access, Immunology (including allergy), Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Psoriatic arthritis treatment and the risk of herpes zoster
Conclusions In our database, the risk of HZ was significantly increased with age, treatment with steroids, and combination of anti-TNF-α agents and c-DMARDs, but not with c-DMARDs or anti-TNF-α therapy alone. Time to HZ event was shorter in patients treated with anti -TNF-α agents.
Source: Annals of the Rheumatic Diseases - December 11, 2015 Category: Rheumatology Authors: Zisman, D., Bitterman, H., Shalom, G., Feldhamer, I., Comanesther, D., Batat, E., Greenberg-Dotan, S., Cohen, S., Cohen, A. D. Tags: Immunology (including allergy), Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis, Epidemiology Clinical and epidemiological research Source Type: research

Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases
Abstract Osteoclasts are multinucleated cells derived from mononuclear phagocyte precursors (monocytes, macrophages); in the canonical pathway of osteoclastogenesis, these cells fuse and differentiate to form specialised bone-resorbing osteoclasts in the presence of receptor activator for nuclear factor kappa B ligand (RANKL). Non-canonical pathways of osteoclastogenesis have been described in which several cytokines and growth factors are able to substitute for RANKL. These humoral factors can generally be divided into those which, like RANKL, are tumour necrosis family (TNF) superfamily members and those which a...
Source: Clinical Reviews in Allergy and Immunology - November 17, 2015 Category: Allergy & Immunology Source Type: research

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
Conclusions Baricitinib improved the signs and symptoms of RA in methotrexate inadequate responders with active disease. Baricitinib was well tolerated with no unexpected safety findings through week 24. Trial registration number NCT01185353.
Source: Annals of the Rheumatic Diseases - January 7, 2015 Category: Rheumatology Authors: Keystone, E. C., Taylor, P. C., Drescher, E., Schlichting, D. E., Beattie, S. D., Berclaz, P.-Y., Lee, C. H., Fidelus-Gort, R. K., Luchi, M. E., Rooney, T. P., Macias, W. L., Genovese, M. C. Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Efficacy and safety of open-label etanercept on extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis and psoriatic arthritis: part 1 (week 12) of the CLIPPER study
Conclusions ETN treatment for 12 weeks was effective and well tolerated in paediatric subjects with eoJIA, ERA and PsA, with no unexpected safety findings.
Source: Annals of the Rheumatic Diseases - April 30, 2014 Category: Rheumatology Authors: Horneff, G., Burgos-Vargas, R., Constantin, T., Foeldvari, I., Vojinovic, J., Chasnyk, V. G., Dehoorne, J., Panaviene, V., Susic, G., Stanevica, V., Kobusinska, K., Zuber, Z., Mouy, R., Rumba-Rozenfelde, I., Breda, L., Dolezalova, P., Job-Deslandre, C., W Tags: Open access, Immunology (including allergy), Pain (neurology), Renal medicine, Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis
Conclusions The findings from this SLR confirm the known safety pattern of sDMARDs and bDMARDs for the treatment of RA.
Source: Annals of the Rheumatic Diseases - February 4, 2014 Category: Rheumatology Authors: Ramiro, S., Gaujoux-Viala, C., Nam, J. L., Smolen, J. S., Buch, M., Gossec, L., van der Heijde, D., Winthrop, K., Landewe, R. Tags: Immunology (including allergy), Biological agents, Connective tissue disease, Degenerative joint disease, Drugs: musculoskeletal and joint diseases, Musculoskeletal syndromes, Rheumatoid arthritis Clinical and epidemiological research Source Type: research